Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 375 of 2051 entries
View as:

Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)

Phase: N/A Priority: Normal
NCT ID: NCT02573181 Org: User:
Start: 10/30/15 End: 01/28/16 Due: 01/28/17

Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)

Phase: N/A Priority: Normal
NCT ID: NCT00758485 Org: User:
Start: 10/31/08 End: 06/30/09 Due: 06/30/10

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)

Phase: N/A Priority: Normal
NCT ID: NCT01295827 Org: User:
Start: 03/04/11 End: 12/11/18 Due: 12/11/19

Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)

Phase: N/A Priority: Normal
NCT ID: NCT03882801 Org: User:
Start: 04/10/19 End: 10/22/19 Due: 10/22/20

Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)

Phase: N/A Priority: Normal
NCT ID: NCT03583333 Org: User:
Start: 09/18/18 End: 07/12/22 Due: 07/12/23

Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism (MK-0000-145)

Phase: N/A Priority: Normal
NCT ID: NCT01138813 Org: User:
Start: 03/31/09 End: 02/28/10 Due: 02/28/11

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)

Phase: N/A Priority: Normal
NCT ID: NCT02622074 Org: User:
Start: 01/27/16 End: 11/18/19 Due: 11/18/20

Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

Phase: N/A Priority: Normal
NCT ID: NCT00733122 Org: User:
Start: 10/01/09 End: 10/01/13 Due: 10/01/14

MK0767 and Metformin Combination Study (0767-028)

Phase: N/A Priority: Normal
NCT ID: NCT00543738 Org: User:
Start: 06/30/03 End: 12/31/03 Due: 12/31/04

Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00952341 Org: User:
Start: 08/25/09 End: 05/05/10 Due: 05/05/11

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00048607 Org: User:
Start: 07/30/02 End: 12/31/03 Due: 12/31/04

A Pharmacokinetic Evaluation Study in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00210054 Org: User:
Start: 11/30/02 End: 12/31/02 Due: 12/31/03

Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)

Phase: N/A Priority: Normal
NCT ID: NCT00963573 Org: User:
Start: 09/30/03 End: 11/30/06 Due: 11/30/07

Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)

Phase: N/A Priority: Normal
NCT ID: NCT00729183 Org: User:
Start: 10/02/08 End: 03/21/11 Due: 03/21/12

Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)

Phase: N/A Priority: Normal
NCT ID: NCT01500707 Org: User:
Start: 01/31/13 End: 07/31/13 Due: 07/31/14

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

Phase: N/A Priority: Normal
NCT ID: NCT01111851 Org: User:
Start: 04/30/10 End: 10/31/10 Due: 10/31/11

Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)

Phase: N/A Priority: Normal
NCT ID: NCT06829225 Org: User:
Start: 06/13/24 End: 11/11/24 Due: 11/11/25

Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-043)

Phase: N/A Priority: Normal
NCT ID: NCT06428383 Org: User:
Start: 07/03/24 End: 04/15/32 Due: 04/15/33

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)

Phase: N/A Priority: Normal
NCT ID: NCT06699355 Org: User:
Start: 11/08/23 End: 12/29/23 Due: 12/29/24

Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)

Phase: N/A Priority: Normal
NCT ID: NCT00670488 Org: User:
Start: 04/15/08 End: 07/11/11 Due: 07/11/12

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Phase: N/A Priority: Normal
NCT ID: NCT03547154 Org: User:
Start: 10/22/98 End: 02/20/01 Due: 02/20/02

Bunionectomy Study (0000-063)

Phase: N/A Priority: Normal
NCT ID: NCT00601458 Org: User:
Start: 07/31/07 End: 01/31/08 Due: 01/31/09

Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)

Phase: N/A Priority: Normal
NCT ID: NCT02613403 Org: User:
Start: 12/10/15 End: 03/27/17 Due: 03/27/18

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00035048 Org: User:
Start: 11/21/01 End: 12/31/03 Due: 12/31/04

A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)

Phase: N/A Priority: Normal
NCT ID: NCT06699329 Org: User:
Start: 01/22/24 End: 05/24/24 Due: 05/24/25